Lerar (Lesinurad) 200mg

$0.99 / Price
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    200mg*30Tablets/Bottle
  • Strength
    200mg
  • Compositon
    Lesinurad
  • Treatment
    Inhibitor used to treat high blood uric acid levels associated with gout, is only recommended with allopurinol or febuxostat.
  • Form
    Tablet
  • Brand
    Lerar
  • Quantity Unit
    30Tablets/Bottle
  • Manufacturer
    TLPH

Brand name: Lelar

Generic name: Lesinurad

Strength:  200mg*30tablets.

Dosage form: Film-coated tablets.


Medication management

Oral administration

Lesinurad is used in combination with xanthine oxidase inhibitors such as allopurinol

Not recommended for patients taking allopurinol <300 mg/day (<200 mg/day if estimated CrCl <60 mL/min)

Concomitant with morning dose of xanthine oxidase inhibitor

If treatment with a xanthine oxidase inhibitor is interrupted, lesinurad should also be interrupted

Patients should be instructed to remain adequately hydrated (eg, 2 liters [68 ounces] of fluids per day)

Failure to follow these instructions may increase the risk of kidney events.


Adverse reactions

1-10%

  • Headache (5.3%)
  • Influenza (5.1%)
  • GERD (2.7%)
  • Kidney failure (1.2%)

serum creatinine

  • Increased creatinine (4.3%)
  • Altitude 1.5 to <2 x baseline (3.9%)
  • Altitude ≥ 2x baseline (1.8%)
  • Nearly 90% of students are resolved by the end of their studies

<1%

  • kidney stones

Hyperuricemia

Hyperuricemia associated with hypertension with xanthine oxidase inhibitor therapy in patients who do not achieve target serum uric acid levels with xanthine oxidase inhibitor alone

200 mg orally once daily in combination with a xanthine oxidase inhibitor (ie, allopurinol or febuxostat)

Not to exceed 200 mg/day.

dose adjustment

renal insufficiency

  • CrCl≥45mL/min: No dose adjustment required
  • CrCl <45 mL/min: do not use recinadide
  • Discontinue lacinadide if estimated CrCl persists <45 mL/min.

Dosage Considerations

Assess renal function before starting treatment and periodically thereafter; monitor estimated CrCl <60 mL/min more frequently

Not recommended for the treatment of asymptomatic hyperuricemia

Do not use as monotherapy; failure to take lacinadide with a xanthine oxidase inhibitor may increase the risk of adverse renal reactions

gout torch

  • Gout flares may occur after initiation of urate lowering therapy, including Rhine strains, due to the flow of urate from tissue deposits due to altered serum uric acid levels
  • Gout prophylaxis is recommended when starting lesinurad, according to practice guidelines
  • Discontinuation of lesinurad is not required if a gout flare occurs during treatment
  • Gout flares should be managed concurrently according to the needs of the patient

storage

Store at 20-25°C (68-77°F); allowable temperature is 15-30°C (59-86°F).


PostAds

Link

Poster

Top